RxDoctor Payments Data

John Sarris, MD

Psychiatry · Poughkeepsie, NYNPI 1356333207

Payments from drug & device makers

$1,394in general payments, 2019–2025

Across 60 payments — averaging $23.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$316
  • Otsuka America Pharmaceutical, Inc.$314
  • Alkermes, Inc.$252
  • Sunovion Pharmaceuticals Inc.$162
  • E.r. Squibb & Sons, L.L.C.$79
  • AbbVie$74
  • plus $198 from 4 others

What the payments were for

  • Food & beverage$1,29493%
  • Education$1007%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,394 in reported general payments places this provider in the 80th percentile of 3,713 psychiatry providers in New York.

See all psychiatry providers in New York

Medicare billing

Part B allowed, 2024
$11,963
Medicare patients
13
Services billed
112

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine51$631,476
AustedoDeutetrabenazine69$586,419
IngrezzaValbenazine Tosylate58$493,131
Invega SustennaPaliperidone Palmitate129$409,061
Abilify MaintenaAripiprazole79$222,406
Invega TrinzaPaliperidone Palmitate14$146,586
AristadaAripiprazole Lauroxil47$116,375
CaplytaLumateperone Tosylate24$41,756
FanaptIloperidone15$29,274
Fluphenazine Hcl51$12,182
Fluphenazine Decanoate57$7,042
Aripiprazole119$6,992
Duloxetine Hcl118$5,980
Divalproex Sodium ErDivalproex Sodium51$5,317
Trazodone Hcl177$4,298

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo, Loxapine$39$1,219,974149 claims
Johnson & JohnsonInvega Sustenna, Invega Trinza$316$555,647143 claims
Neurocrine Biosciences, Inc.Ingrezza$61$493,13158 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$314$222,40679 claims
Alkermes, Inc.Aristada$252$116,37547 claims
Vanda Pharmaceuticals Inc.Fanapt$55$29,27415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,713 psychiatry providers in New York.

Other psychiatry in Poughkeepsie

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →